86 search results for Lung

About the NCCN Guidelines for Patients

2024 APEX Award of Excellence for the NCCN Guidelines for Patients: Metastatic Non-Small Cell Lung

ORP Grant History

lung cancer AstraZeneca Pharmaceuticals, LP – quality improvement/ projects in ovarian cancer AstraZeneca Pharmaceuticals, LP – quality improvement/ projects in small cell lung cancer AstraZeneca Pharmaceuticals, LP – quality improvement/ projects in early-stage non-small cell lung cancer, with afatinib in lung cancer Bristol-Myers Squibb Company and ImClone Systems Incorporated, , and bevaciumab, with or without atezolizumab, in lung cancer GlaxoSmithKline LLC – pre-clinical

Transparency Process

Resume Screening

Neuroendocrine and Adrenal Tumors Non-Small Cell Lung Cancer Occult Primary Ovarian Cancer, Cancer Small Bowel Adenocarcinoma Small Cell Lung Cancer Soft Tissue Sarcoma Squamous Cell Skin, /Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric Lung Cancer Screening, Kidney Cancer Liver Cancer Lung Cancer Screening Mantle Cell Lymphoma Marginal Zone Lymphomas, Nausea and Vomiting Neuroendocrine Tumors Non-Small Cell Lung Cancer - Early and Locally

Permission to Cite or Use NCCN Content

Cancer Lung Cancer Screening Management of Immunotherapy-Related Toxicities Melanoma: Cutaneous, Cell Lung Cancer Occult Primary Older Adult Oncology Ovarian Cancer/Fallopian Tube Cancer/Primary, Adenocarcinoma Small Cell Lung Cancer Smoking Cessation Soft Tissue Sarcoma Squamous Cell Skin Cancer, Neuroendocrine and Adrenal Tumors Non-Small Cell Lung Cancer Occult Primary Ovarian Cancer/Fallopian Tube, Adenocarcinoma Small Cell Lung Cancer Soft Tissue Sarcoma Squamous Cell Skin Cancer Systemic

The Alliance for Cancer Care Equity (ACCE) 

When autocomplete results are available use up and down arrows to review and enter to select. NCCN and Taiho Request for Proposals (RFP) Grant Opportunity: Phase I/II Clinical Trials of Zipalertinib (CLN 081/TAS 6417) for Non-Small Cell Lung Cancers with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Uncommon/Compound Mutations – Proposal Submission

Current Opportunities

Neuroblastoma Neuroendocrine and Adrenal Tumors Non-Small Cell Lung Cancer Occult Primary, Cancer Rectal Cancer Small Bowel Adenocarcinoma Small Cell Lung Cancer Soft Tissue Sarcoma, , and Prostate Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric Lung Cancer, Checkpoint Inhibitors Kidney Cancer Liver Cancer Lung Cancer Screening Mantle Cell Lymphoma Marginal, Nasopharyngeal Cancer Nausea and Vomiting Neuroendocrine Tumors Non-Small Cell Lung Cancer - Early

Guidelines Panels

Lung Cancer Screening Panel, Panel Non-Small Cell Lung Cancer, Small Cell Lung Cancer Panel

Harmonized Guidelines

and Adrenal Tumors Version 1.2022 Non-Small Cell Lung Cancer Version 4.2024 Occult, Cell Lung Cancer Version 2.2024 Soft Tissue Sarcoma Version 2.2022 Testicular, Guidelines™ (Vietnam) - Guidelines for Treatment of Cancer by Type Non-Small Cell Lung Cancer Version 3.2023 (English) Non-Small Cell Lung Cancer Version 3.2023 (Vietnamese

Guidelines for Patients

Version: 2023 Lung Cancer Screening, : 2022 Non-Small Cell Lung Cancer - Early and Locally Advanced Version: 2024 Non-Small Cell Lung Cancer, Version: 2024 Small Cell Lung Cancer

NCCN_Oncology_Research_Program_Brochure

of patients with suspected or newly diagnosed lung cancer in Antelope Valley, one of the most underserved regions of Southern California. Antelope Valley has the highest rate of lung cancer mortality, of the first lung cancer screening program in Antelope Valley. This initiative has touched many, and treatment of lung cancer in this underserved area.” Dan J. Raz, MD City of Hope National Medical Center

Detection, Prevention, and Risk Reduction

Lung Cancer Screening Version: 1.2025

2023 Summit Report

• Kristen Santiago, LUNGevity • Lisa Schlager, FORCE

Annual Report

for Breast Cancer 1,318,623 Downloads NCCN Guidelines for Non-Small Cell Lung Cancer 932,195, Cell Lung Cancer are currently available in English and Vietnamese. NCCN 2024 Annual Report 18, at meetings including: - World Conference on Lung Cancer - American Association for Cancer Research

International Adaptations

2.2022 (English) Non-Small Cell Lung Cancer Version 3.2022 (English

cancer_across_life_span

u k e m i a & Lymphoma Society 15 LUNGevity Foundation 16 Lymphoma Research Foundation 17, Phone: 800-955-4572 Email: [email protected] NCCN Digital Resource Booklet 16 LUNGevity Foundation LUNGevity Foundation is the nation’s l e a d i n g l u n g c a n c e r o r g a n i z a t i o n f o c u s e d o n i m p roving outcomes for people with lung cancer through research, education, policy initiatives, and support and engagement for patients, survivors and caregivers. LUNGevity

NCCN Guidelines for Patients with Permission Email

Hodgkin Lymphoma Kidney Cancer Lung Cancer: Early and Locally Advanced Metastatic Malignant, e a a n d Vomiting Cancer Screening Lung Cancer Screening Age-Related Adolescents and Yo u n g, Invasive Metastatic Colon Cancer Kidney Cancer Lung Cancer: Early and Locally Advanced

2021-State-Oncology-Society-Forum-Summary

Cancer Action Network, Cancer Support Community, LUNGevity, and NCCN. It included an overview

PAS Policy Report Precision Medicine Final

for the appropriate biomarker tests. Lung and other cancers require significant surgical intervention

HIT

Neoplasms Neuroblastoma Neuroendocrine and Adrenal Tumors Non-Small Cell Lung Cancer Occult Primary, Prostate Cancer Rectal Cancer Small Bowel Adenocarcinoma Small Cell Lung Cancer Soft Tissue Sarcoma, , and Prostate Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric Lung Cancer, Checkpoint Inhibitors Kidney Cancer Liver Cancer Lung Cancer Screening Mantle Cell Lymphoma, Nasopharyngeal Cancer Nausea and Vomiting Neuroendocrine Tumors Non-Small Cell Lung Cancer